Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Allied Biotech's share price for the quarter that ended in Dec. 2025 was NT$23.1. Allied Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 96.2 Mil. Therefore, Allied Biotech's market cap for the quarter that ended in Dec. 2025 was NT$2,223.2 Mil.
Allied Biotech's quarterly market cap
declined
from Jun. 2025 (NT$1,843.7 Mil) to Sep. 2025 (NT$1,684.3 Mil) but then
increased
from Sep. 2025 (NT$1,684.3 Mil) to Dec. 2025 (NT$2,223.2 Mil).
Allied Biotech's annual market cap
increased
from Dec. 2023 (NT$1,564.4 Mil) to Dec. 2024 (NT$1,666.0 Mil) and
increased
from Dec. 2024 (NT$1,666.0 Mil) to Dec. 2025 (NT$2,223.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Allied Biotech's Enterprise Value for Today is NT$2,312.0 Mil.
Allied Biotech (ROCO:1780) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Allied Biotech Market Cap Related Terms
Allied Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Allied Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Allied Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allied Biotech Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allied Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Allied Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Allied Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allied Biotech (ROCO:1780) has a Market Cap of NT$2,432.4 Mil as of Jul. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Allied Biotech and its competitors. According to the industry distribution chart, Allied Biotech ranks #654 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 63.9%.
Is Allied Biotech's Market Cap too high?
Allied Biotech's current Market Cap is NT$2,432.4 Mil. Based on the distribution chart, Allied Biotech ranks #654 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Allied Biotech has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Allied Biotech's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allied Biotech ranks #654 out of 1023 companies for Market Cap. This places Allied Biotech in the lower half of its industry. The industry median Market Cap is 216.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 216.46, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Allied Biotech and its competitors. For the Drug Manufacturers industry, the median Market Cap is 216.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allied Biotech's current Market Cap is NT$2,432.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied Biotech stock overvalued right now?
Based on GuruFocus' analysis, Allied Biotech (ROCO:1780) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.77, compared to a current price of NT$22.30 — trading 7.4% above its estimated fair value. The current Market Cap is NT$2,432.4 Mil. Allied Biotech's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Allied Biotech (ROCO:1780), the current Market Cap is NT$2,432.4 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allied Biotech (ROCO:1780) Overvalued in 2026?
Based on GuruFocus' analysis, Allied Biotech stock appears to be overvalued.
The current stock price of NT$22.30 is trading 7.4% above its estimated GF Value™ of NT$20.77.
GuruFocus considers Allied Biotech to be Fairly Valued.
Key valuation signals for ROCO:1780:
Market Cap: NT$2,432.4 Mil
GF Value™: NT$20.77 vs. price of NT$22.30 (7.4% above fair value)
No single metric tells the full story. See the ROCO:1780 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allied Biotech Corp is a Taiwan based manufacturer of carotenoids. It manufactures carotenoid formulations for the food, supplement and feed industries. The company markets its products under the name Altratene.
77GF Score
Get the complete analysis for ROCO:1780
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1780 has been successfully added to your 
